Current shareholders or people or entities who were once current shareholders are in the same place that they've been for years. As far as whether to sell/license Brilacidin (or not and for how much) for any purpose they are subject to the whims of one man. Some, perhaps many, are perfectly happy with that.
In theory the Board should review and consider any given whim but there's no evidence that those two remaining gentlemen have any real input at all. They were appointed for one reason, the wrong reason, and haven't been heard from since the time of their appointments. Sadly this is not unheard of in the OTC marketplace.
"Where does that leave current shareholders, in your humble opinion?"
Some of my opinions are humble....this isn't one of them (it's a fact, not an opinion). If the CEO chooses to license/sell B on terms that some or all of the other shareholders aren't happy with their only recourse is in the Court system.
News 
Market Data 
Discover 
